Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Epilepsia. 2011 Aug 19;52(9):1666–1677. doi: 10.1111/j.1528-1167.2011.03220.x

Table 1. Distribution of experimental groups, prenatal exposures, and postnatal pretreatments.

For P10 rats 5 mg/kg of NMDA was used, 7.5 mg/kg of NMDA for P12 rats, 12 mg/kg of NMDA for P13 rats, and 15 mg/kg of NMDA for P15 rats were used. NMDA was administered intraperitoneally always in the volume of 10 ml/kg of saline.

Experiment Group identification Numbers
of rats		 Prenatal exposure;
gestational day		 Postnatal (AED) pretreatment,
postnatal day		 Postnatal trigger of
spasms, postnatal day
Clustering of
spasms
(Figure 1)		 P10 saline n=7 saline G15 none NMDA P10
betamethasone n=9 betamethasone G15 none NMDA P10
P15 saline n=6 saline G15 none NMDA P15
betamethasone n=5 betamethasone G15 none NMDA P15
Repeated trigger of
spasms (Figure 2)		 saline n=7 saline G15 none NMDA P12, P13, P15
betamethasone n=9 betamethasone G15 none NMDA P12, P13, P15
Randomized ACTH
trial (Figure 3)		 saline n=11 betamethasone G15 saline 2× P12, 3× P13, 3× P14 NMDA P12, P13, P15
ACTH n=11 betamethasone G15 ACTH 0.3 mg/kg, 2× P12, 3x
P13, 3× P14		 NMDA P12, P13, P15
Pharmacology of
the model
(Figure 4)		 saline n=4 betamethasone G15 saline P14 NMDA P15
GVG 100 n=7 betamethasone G15 vigabatrin 100 mg/kg P14 NMDA P15
GVG 250 n=8 betamethasone G15 vigabatrin 250 mg/kg P14 NMDA P15
saline n=16 betamethasone G15 saline P15 NMDA P15
MPD 5 n=10 betamethasone G15 methylprednisolone 5 mg/kg
P15		 NMDA P15
MPD 20 n=8 betamethasone G15 methylprednisolone 20 mg/kg
P15		 NMDA P15
MPD 60 n=7 betamethasone G15 methylprednisolone 60 mg/kg
P15		 NMDA P15
saline P13-P15 n=6 betamethasone G15 saline P13, P14, P15 NMDA P15
MPD P13-P15 n=9 betamethasone G15 methylprednisolone 60 mg/kg
P13, P14, P15		 NMDA P15
vehicle 24 hours n=9 betamethasone G15 1% alcohol P14 NMDA P15
rapamycin 24 hours n=10 betamethasone G15 rapamycin 3 mg/kg P14 NMDA P15
vehicle P7-P14 n=4 betamethasone G15 1% alcohol daily P7-P14 NMDA P15
rapamycin P7-P14 n=9 betamethasone G15 rapamycin 3 mg/kg daily P7
-P14		 NMDA P15
Behavioral outcome
(Figure 5)		 saline – no spasms n=11 betamethasone G15 none saline P15
P15 spasms n=11 betamethasone G15 none NMDA P15
serial spasms n=6 betamethasone G15 none NMDA P12, P13, P15
saline-3×3 n=9 betamethasone G15 saline 3× P12, 3× P13, 3× P14 NMDA P15
ACTH-3×3 n=10 betamethasone G15 ACTH 0.3 mg/kg, 3× P12, 3×
P13, 3× P14		 NMDA P15
saline ×3 n=4 betamethasone G15 saline P13, P14, P15 NMDA P15
MPD 60 ×3 n=3 betamethasone G15 methylprednisolone 60 mg/kg
P13, P14, P15		 NMDA P15